Interpace Biosciences
CMS Contractor Novitas Rescinds Noncoverage Decision for Cancer Genetic Tests
The original decision rescinded coverage for tests from Castle Biosciences, Pacific Edge Diagnostics, Interpace Biosciences, Abbott, Clinical Genomics, and the University of Pittsburgh Medical Center.
CMS Contractor Novitas Rescinds Coverage for Multiple Cancer Genetic Tests
Novitas reviewed, analyzed, and published literature for a variety of genetic oncology tests and highlighted several that it claims are not medically reasonable or necessary.
Interpace Biosciences to Stop Offering Pancreatic Cancer Test After Losing CMS Reimbursement
Novitas said in its coverage determination that the test has not demonstrated incremental clinical value in the prognosis of pancreatic cysts and associated cancer.
In Brief This Week: Interpace Biosciences, ProPhase Labs, OpGen, Centogene, Seegene, Freenome, More
News items for the week of March 27, 2023.
Earnings Roundup: Lucira Health, Interpace Biosciences, Lucid Diagnostics
The diagnostics firms posted their quarterly financial results this week.
Jan 13, 2022
Interpace Commences $30M Rights Offering
Nov 11, 2021
Interpace Biosciences Q3 Revenues Rise 15 Percent
Aug 11, 2021
Interpace Biosciences Q2 Revenues More Than Double
May 12, 2021
Interpace Biosciences Q1 Revenues Up 8 Percent
Jan 20, 2021
Interpace Bio Q3 Revenues Rise 6 Percent
Oct 20, 2020
Interpace Biosciences Q2 Revenues Decline 14 Percent
Jun 26, 2020